Combination therapy using TGF-β1 and STI-571 can induce apoptosis in BCR-ABL oncogene-expressing cells

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Signaling

Background:

• Chronic myeloid leukemia (CML) is characterized by the BCR-ABL oncogene, a tyrosine kinase that inhibits the TGF-β1 signaling pathway.
• Resistance to tyrosine kinase inhibitors like STI-571 necessitates exploring alternative therapeutic strategies.
• Understanding the interplay between BCR-ABL, STI-571, and TGF-β1 signaling is crucial for CML treatment.

Purpose of the Study:

• To investigate the combined effects of STI-571 and TGF-β1 on K562 cells, a CML cell line.
• To evaluate the impact of this combination therapy on cell survival, apoptosis, and cell cycle progression.
• To determine if TGF-β1 influences the efficacy of STI-571 in K562 cells.

Main Methods:

• K562 cells were treated with STI-571, TGF-β1, or a combination of both.
• Analysis of cell signaling pathways, including survival and apoptosis markers.
• Flow cytometry was used to assess cell cycle arrest (sub-G1 phase) and apoptosis (Annexin V staining).

Main Results:

• TGF-β1 treatment activated cell signaling pathways involved in survival and apoptosis in K562 cells.
• STI-571 treatment alone induced apoptosis, reducing proteins like Bcl-xL, Bcl-2, p-AKT, and increasing PARP cleavage and p27.
• Combination therapy significantly enhanced sub-G1 cell cycle arrest and triggered apoptotic signaling more strongly than individual treatments.

Conclusions:

• Combined treatment with STI-571 and TGF-β1 promotes sub-G1 cell cycle arrest and robust apoptosis in K562 cells.
• TGF-β1 does not impede the apoptotic effects of STI-571; rather, it potentiates them.
• AKT protein phosphorylation remains effective in mediating apoptosis under combination therapy, suggesting therapeutic potential.